Trademark: 97576363
Word
JEL
Status Date
Thursday, March 14, 2024
Filing Date
Friday, September 2, 2022
Published for Opposition
Tuesday, April 23, 2024
5 Glaucoma agents; Irrigating solutions for eye use; Medicated eye washes; Eye drops; Ocular pharmaceuticals; Ophthalmic preparations; Ophthalmologic preparations; Pharmaceutical preparations for ocular or intraocular surgery; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical products for ophthalmological use; Dermatological pharmaceutical products; Medical preparations, namely, foot, hand and skin creams for diabetics; Medicated dermatological preparations and substances; Medicated skin preparation for use in treating wound healing; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for treating skin disorders; Pharmaceutical preparations for use in dermatology; Medicated ointments for treating dermatological conditions; Medicated skin care preparations, namely, creams, lotions, gels, toners, cleaners and peels; Medicated skin care preparations; Pharmaceutical preparation for skin care; Pharmaceutical preparations for skin care; Medicinal creams for skin care; Frostbite salve for pharmaceutical purposes; Poultices; Gelatine for medical purposes; wound-healing ointments for pharmaceutical purposes; Sunburn ointments; Acne treatment preparations; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of gel that facilitate the delivery of pharmaceutical preparations; Pharmaceutical preparations for prostatic diseases and conditions; Pharmaceutical preparations for benign prostatic hyperplasia; Pharmaceutical preparations for the treatment and prevention of prostatic diseases and conditions; Pharmaceutical preparations for the treatment and prevention of benign prostatic hyperplasia
The mark consists of JeL in a stylized font.
Color is not claimed as a feature of the mark.
"GEL"
Apr 3, 2024
Notification Of Notice Of Publication E-Mailed
Mar 13, 2024
Approved For Pub - Principal Register
Mar 6, 2024
Teas/Email Correspondence Entered
Mar 6, 2024
Correspondence Received In Law Office
Mar 6, 2024
Teas Request For Reconsideration Received
Dec 11, 2023
Notification Of Final Refusal Emailed
Dec 11, 2023
Final Refusal E-Mailed
Dec 11, 2023
Final Refusal Written
Sep 4, 2023
Teas/Email Correspondence Entered
Sep 4, 2023
Correspondence Received In Law Office
Sep 4, 2023
Teas Response To Office Action Received
Jul 6, 2023
Notification Of Non-Final Action E-Mailed
Jul 6, 2023
Non-Final Action E-Mailed
Jul 6, 2023
Non-Final Action Written
Jun 20, 2023
Assigned To Examiner
Jan 11, 2023
Teas Change Of Correspondence Received
Jan 11, 2023
Attorney/Dom.Rep.Revoked And/Or Appointed
Jan 11, 2023
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Sep 21, 2022
New Application Office Supplied Data Entered
Sep 6, 2022
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
